D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They currently have a $5.00 price objective on the stock.

VNRX has been the subject of a number of other research reports. StockNews.com assumed coverage on VolitionRx in a research note on Friday, January 31st. They issued a “sell” rating for the company. Benchmark reissued a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Stock Up 0.8 %

Shares of VolitionRx stock traded up $0.00 on Thursday, hitting $0.59. The stock had a trading volume of 26,009 shares, compared to its average volume of 98,868. VolitionRx has a one year low of $0.43 and a one year high of $1.22. The stock has a market cap of $54.58 million, a price-to-earnings ratio of -1.64 and a beta of 1.20. The stock’s 50-day simple moving average is $0.62 and its two-hundred day simple moving average is $0.65.

Insider Buying and Selling at VolitionRx

In other news, Director Guy Archibald Innes purchased 174,764 shares of the business’s stock in a transaction on Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the purchase, the director now directly owns 617,085 shares in the company, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Cameron John Reynolds purchased 139,811 shares of the business’s stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, with a total value of $79,692.27. Following the completion of the purchase, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 358,266 shares of company stock valued at $204,212. 12.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC increased its holdings in VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is currently owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.